Targeting Hepatocellular Carcinoma: What did we Discover so Far?

scientific article

Targeting Hepatocellular Carcinoma: What did we Discover so Far? is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4081/ONCOL.2016.302
P932PMC publication ID5136756
P698PubMed publication ID27994769

P50authorAna Filipa BritoQ114446544
José Guilherme TralhãoQ114446545
Ana Margarida AbrantesQ38589353
Maria Filomena BotelhoQ39051211
P2860cites workGlobal cancer statisticsQ22241238
Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89Q24685729
Liver-Directed Radiotherapy for Hepatocellular CarcinomaQ26738869
New advances in hepatocellular carcinomaQ26749329
Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific RegionQ26750444
Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinomaQ26773251
Systemic therapies for hepatocellular carcinomaQ26775193
Targeting the insulin-like growth factor pathway in hepatocellular carcinomaQ27006846
Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapiesQ27026025
Management of hepatocellular carcinoma: An updateQ27860530
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008Q27860674
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingQ28296761
Hepatocellular carcinoma: epidemiology and molecular carcinogenesisQ28306363
Management of hepatocellular carcinomaQ29616230
Epidemiology of viral hepatitis and hepatocellular carcinomaQ29617918
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosisQ29619508
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.Q33368982
p53 and chemosensitivity.Q33779334
Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinomaQ33788566
The role of p53-target genes in human cancerQ33861549
Non-viral causes of hepatocellular carcinomaQ34041381
Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: an alternative mechanism of HBx-related pathogenesisQ34068117
Systemic chemotherapy of liver tumorsQ34110952
Molecular pathogenesis of human hepatocellular carcinoma.Q34167480
Genetic and epigenetic events in human hepatocarcinogenesisQ34250052
Prognostic prediction and treatment strategy in hepatocellular carcinoma.Q34547469
Natural history of hepatocellular carcinoma and current treatment optionsQ34587869
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspectiveQ34625481
The prognostic molecular markers in hepatocellular carcinomaQ34668320
Role of radiotherapy in the management of hepatocellular carcinoma: A systematic reviewQ34966816
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challengesQ35501246
Hepatocellular carcinoma and chemotherapy: the role of p53.Q39222765
Human augmenter of liver regeneration is important for hepatoma cell viability and resistance to radiation-induced oxidative stressQ39823488
Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma modelQ40417528
Dysregulation of apoptosis in hepatocellular carcinoma cellsQ43166036
Fluorine-18 Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma: Correlation with Glucose Transporters and p53 ExpressionQ43189620
Phase II study of sorafenib in patients with advanced hepatocellular carcinomaQ80112177
MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancersQ80806778
Intracellular signaling and hepatocellular carcinomaQ35586439
Focus on hepatocellular carcinoma.Q35721877
Environmental factors and risk for hepatocellular carcinomaQ35929261
Modulation of apoptosis as a target for liver diseaseQ36066290
Updated treatment approach to hepatocellular carcinoma.Q36097844
Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into PracticeQ36199751
Survival and apoptosis: a dysregulated balance in liver cancerQ36740628
TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancerQ36777331
Targeted therapies for hepatocellular carcinoma.Q36928888
Hepatocellular carcinoma: epidemiology and clinical aspects.Q37025200
Hepatocellular carcinoma--epidemiological trends and risk factorsQ37527585
Systemic therapies in hepatocellular carcinomaQ37527632
Hepatocellular carcinoma: A global view.Q37589349
Approach to radiation therapy in hepatocellular carcinomaQ37661759
Mechanisms of HBV-related hepatocarcinogenesisQ37698774
Role of estrogen in hepatocellular carcinoma: is inflammation the key?Q37710885
Systemic therapy for advanced hepatocellular carcinoma: past, present, and futureQ37734197
Future perspectives in hepatocellular carcinomaQ37765050
Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): Molecular mechanisms and novel paradigmsQ37776350
Advanced hepatocellular carcinoma. Review of targeted molecular drugs.Q37837305
Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).Q37983026
Emerging targeted strategies in advanced hepatocellular carcinomaQ38086183
Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-GlucoseQ38213800
Understanding the tumor suppressor PTEN in chronic alcoholism and hepatocellular carcinomaQ38271796
Fas and TRAIL 'death receptors' as initiators of inflammation: Implications for cancerQ38345723
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implicationsQ38400354
Sorafenib: 10 years after the first pivotal trial.Q38544841
The rationale for targeting TGF-β in chronic liver diseases.Q38715538
Influence of P53 on the radiotherapy response of hepatocellular carcinoma.Q38822712
P275copyright licenseCreative Commons Attribution-NonCommercial 4.0 InternationalQ34179348
P6216copyright statuscopyrightedQ50423863
P433issue2
P407language of work or nameEnglishQ1860
P921main subjecthepatocellular carcinomaQ1148337
P304page(s)302
P577publication date2016-10-10
P1433published inOncology reviewsQ26841967
P1476titleTargeting Hepatocellular Carcinoma: What did we Discover so Far?
P478volume10

Reverse relations

cites work (P2860)
Q91940339A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance
Q41549246A proteomics-based investigation on the anticancer activity of alisertib, an Aurora kinase A inhibitor, in hepatocellular carcinoma Hep3B cells
Q45872155Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: First evidence in preclinical hepatocellular carcinoma
Q40070928Extrahepatic metastasis of hepatocellular carcinoma to the paravertebral muscle: A case report.
Q41413012High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes
Q64091327Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
Q91179083MERIT: Systematic Analysis and Characterization of Mutational Effect on RNA Interactome Topology
Q59354957Mutations in and nucleotide excision repair genes are correlated with prognosis of hepatitis B virus-associated hepatocellular carcinoma
Q58796653NFATc1 is a tumor suppressor in hepatocellular carcinoma and induces tumor cell apoptosis by activating the FasL-mediated extrinsic signaling pathway
Q58579029Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
Q57119938Tsumura-Suzuki obese diabetic mice-derived hepatic tumors closely resemble human hepatocellular carcinomas in metabolism-related genes expression and bile acid accumulation
Q41618935miRNA-346 promotes proliferation, migration and invasion in liver cancer

Search more.